AVALO THERAPEUTICS, INC. Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles
AVALO THERAPEUTICS, INC. (AVTX) reported Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles of $6.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-11.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles · last filed 2020-03-11
- AVALO THERAPEUTICS, INC. business combination, provisional information, initial accounting incomplete, adjustment, intangibles for fiscal 2018 was $6.00K.
| Period end | Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles 12 month | Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles 12 month as first filed |
|---|---|---|
| 2018-12-31 | $6.00K 10-K · filed 2020-03-11 | $1.53M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |